Smallpox vaccination: a review, part II. Adverse events
- PMID: 12856218
- DOI: 10.1086/375825
Smallpox vaccination: a review, part II. Adverse events
Abstract
Smallpox vaccination of health care workers, military personnel, and some first responders has begun in the United States in 2002-2003 as one aspect of biopreparedness. Full understanding of the spectrum of adverse events and of their cause, frequency, identification, prevention, and treatment is imperative. This article describes known and suspected adverse events occurring after smallpox vaccination.
Similar articles
-
Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions.Clin Infect Dis. 2003 Jul 15;37(2):241-50. doi: 10.1086/375824. Epub 2003 Jul 10. Clin Infect Dis. 2003. PMID: 12856217 Review.
-
Transmission of vaccinia virus and rationale for measures for prevention.Clin Infect Dis. 2003 Jul 15;37(2):281-4. doi: 10.1086/377236. Epub 2003 Jun 27. Clin Infect Dis. 2003. PMID: 12856220
-
Smallpox Vaccine Adverse Events Monitoring and Response System for the first stage of the smallpox vaccination program.MMWR Morb Mortal Wkly Rep. 2003 Feb 7;52(5):88-9, 99. MMWR Morb Mortal Wkly Rep. 2003. PMID: 12588007
-
Smallpox vaccination--implications for the occupational health professional.AAOHN J. 2003 Jun;51(6):240-2. AAOHN J. 2003. PMID: 12846455
-
Smallpox vaccine: contraindications, administration, and adverse reactions.Am Fam Physician. 2003 Sep 1;68(5):889-96. Am Fam Physician. 2003. PMID: 13678138 Review.
Cited by
-
A Pseudovirus Nanoparticle Displaying the Vaccinia Virus L1 Protein Elicited High Neutralizing Antibody Titers and Provided Complete Protection to Mice against Mortality Caused by a Vaccinia Virus Challenge.Vaccines (Basel). 2024 Jul 26;12(8):846. doi: 10.3390/vaccines12080846. Vaccines (Basel). 2024. PMID: 39203972 Free PMC article.
-
CD127+CCR5+CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia virus and precede development of interleukin-2+ memory CD4+ T cells.J Virol. 2006 Oct;80(20):10151-61. doi: 10.1128/JVI.02670-05. J Virol. 2006. PMID: 17005692 Free PMC article.
-
Smallpox vaccines: targets of protective immunity.Immunol Rev. 2011 Jan;239(1):8-26. doi: 10.1111/j.1600-065X.2010.00975.x. Immunol Rev. 2011. PMID: 21198662 Free PMC article. Review.
-
Development of ST-246® for Treatment of Poxvirus Infections.Viruses. 2010 Nov;2(11):2409-2435. doi: 10.3390/v2112409. Epub 2010 Nov 3. Viruses. 2010. PMID: 21994624 Free PMC article.
-
Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.J Virol. 2014 Oct;88(19):11339-55. doi: 10.1128/JVI.01491-14. Epub 2014 Jul 16. J Virol. 2014. PMID: 25031354 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical